---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-096268"
form_type: "8-K"
ticker: "CTXR"
cik: "0001506251"
company_name: "Citius Pharmaceuticals, Inc."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T01:48:57.222693+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Citius reports 27% ORR in Phase I trial of pembrolizumab + LYMPHIR for recurrent solid tumors

## Summary
- 27% objective response rate (4/15) and 33% clinical benefit rate; median PFS 57 weeks for patients with clinical benefit.
- Trial enrolled 21 patients; three more to enroll before Phase I portion completes.
- Combination well-tolerated; only one DLT (capillary leak syndrome) at 12 mcg/kg; no serious immune-related AEs.
- Two of four partial responders had prior anti-PD-1 therapy, suggesting potential in checkpoint-resistant patients.
- Phase II expansion planned across broader solid tumor types including gynecologic and other histologies.

## SEC filing metadata
- accession: 0001213900-24-096268
- form_type: 8-K
- ticker: CTXR
- cik: 0001506251
- company_name: Citius Pharmaceuticals, Inc.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1506251/000121390024096268/0001213900-24-096268-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1506251/000121390024096268/ea0220670-8k_citius.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-096268
- JSON: https://secwatch.observer/filing/0001213900-24-096268.json
- Plain text: https://secwatch.observer/filing/0001213900-24-096268.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.